

Opthea Limited Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

<https://marketpublishers.com/r/CFC55EDCC6EBEN.html>

Date: May 2025

Pages: 50

Price: US\$ 499.00 (Single User License)

ID: CFC55EDCC6EBEN

Abstracts

Opthea Limited Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Opthea Limited and its competitors. This provides our Clients with a clear understanding of Opthea Limited position in the [Pharmaceuticals and Biotechnology](#) Industry.

The report contains detailed information about Opthea Limited that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for Opthea Limited. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The Opthea Limited financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-

term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes Opthea Limited competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Opthea Limited business.

About Opthea Limited

Circadian Technologies Limited (the company) provides management and funding for the development and commercialisation of Australian biomedical research. The company aims to identify high potential investment opportunities from within Australian universities and research institutes, focussing on projects which have the potential to address large markets or significant unmet medical needs. Circadian is able to provide funds for further development in addition to providing the management expertise that is essential if the project is to meet its goal of commercialisation.

The company has holdings in Circadian has shareholdings in Optiscan Imaging Limited, Metabolic Pharmaceuticals Limited, Antisense Therapeutics Limited and U.S. based Axon Instruments Inc. Circadian is also the major shareholder in Amrad Corporation Limited, an Australian pharmaceutical research company.

Circadian maintains an active research and development program, including its core neurosciences and cancer projects: development of a potential new treatment for Alzheimer's Disease, development of novel compounds for the potential treatment of a range of neurodegenerative disorders, development of new analgesics with similar properties to morphine but potentially without the undesirable effects on the central nervous system, identification of memory enhancing compounds based on specific brain

receptors, development of a test for cancers of unknown primary, a novel technology for identification of cancer markers (with possible diagnostic as well as therapeutic applications).

The company's other research projects include: a new environmentally friendly process for manufacture of a key pharmaceutical raw material (ephedrine) and an extensive patent portfolio in an emerging technology in gene testing (known as in situ hybridisation).

Holdings

Optiscan Imaging

Optiscan Imaging (Circadian holding 8%) is involved in research and development in biomedical imaging, with core technology in live microscopic imaging for clinical examinations. Optiscan is a Melbourne-based R&D company engaged in medical imaging, whose core technology enables live microscopic imaging at the sub-cellular level for clinical examinations. Their projects and products are based on patented optical-fibre technology (enabling high-magnification microscopes to be miniaturised) and confocal imaging principles (enabling clinicians to look below the tissue surface). The technology serves as a platform that has a variety of potential applications for medicine, science and industry.

Metabolic Pharmaceuticals

Circadian currently holds approximately 22% of Metabolic Pharmaceuticals Limited. Metabolic Pharmaceuticals is an R&D company (Circadian holding 22%) developing therapies for metabolic diseases with application to large global markets. Metabolic is developing therapies for metabolic diseases with application to large global markets, including obesity and obesity-related diseases such as type 2 diabetes.

Their major project is to develop AOD9604, a potential anti-obesity drug developed at Monash University. This compound is modelled on the fat-reducing region of the naturally occurring human growth hormone molecule, and is currently in Phase 2 clinical trials.

Axon Instruments

Axon Instruments (Circadian holding 15%) develops and manufactures high-technology

devices and software for drug discovery.

Their main product areas are:

Cellular Neurosciences: hardware and software products for cellular electrophysiology that measure the tiny electrical currents that modulate electrical signalling between cells;

Microarray Analysis: scanners and analysis software for microarrays of biological samples, such as protein or tissue arrays; and

Cell-Based Screening: workstations for cell-based pharmaceutical screening using high-resolution fluorescence imaging and electrophysiological recording and analysis.

Antisense Therapeutics

In collaboration with its technology and scientific partners, Antisense Therapeutics (Circadian holding 27%) is seeking to develop a pipeline of antisense drugs for a range of medical conditions, including multiple sclerosis and psoriasis.

Antisense Therapeutics is seeking to develop antisense drugs for a range of medical conditions where there are large and/or poorly met markets. It has established a key strategic collaboration with one of the global leaders in antisense technology, US-based ISIS Pharmaceuticals, Inc.

Antisense aims to build on its core collaborations with ISIS and the Melbourne-based Murdoch Childrens Research Institute to research and develop antisense drugs, and to commercialise those that are shown to be successful in clinical testing by entering into licensing deals or other partnerships with major pharmaceutical companies.

Amrad Corporation

Amrad Corporation (Circadian holding 22%) is a biotechnology research and development company with a portfolio including potential treatments for a range of diseases. Amrad Corporation Limited is a biotechnology research and development company based in Melbourne, Australia. Their core business is the research and development of medicines to treat human diseases, and their portfolio of R&D compounds has resulted both from in-house research and from collaborations with Australian medical research institutes.

Amrad progresses its drug discoveries using its own resources or in collaboration with international pharmaceutical companies. It has research collaborations with several overseas companies, including Merck, Serono and Cambridge Antibody Technology. Their portfolio includes compounds in a range of therapeutic areas. One product, emfilermin for treatment of infertility, is in an international Phase 2 clinical trial being conducted by Serono.

Significant Events

On December 7, 2009, CSIRO (Commonwealth Scientific and Industrial Research Organisation) announced a long-term research alliance agreement between the company and Circadian Technologies, to develop potential treatments for cancer.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. OPTHEA LIMITED COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

2. OPTHEA LIMITED BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

3. OPTHEA LIMITED SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

4. OPTHEA LIMITED FINANCIAL ANALYSIS

- 4.1. Financial Statements
 - 4.1.1. Income Statement
 - 4.1.2. Balance Sheet
 - 4.1.3. Cash Flow
- 4.2. Financial Ratios
 - 4.2.1. Profitability
 - 4.2.2. Margin Analysis

- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

5. OPTHEA LIMITED COMPETITORS AND INDUSTRY ANALYSIS

- 5.1. Opthea Limited Direct Competitors
- 5.2. Comparison of Opthea Limited and Direct Competitors Financial Ratios
- 5.3. Comparison of Opthea Limited and Direct Competitors Stock Charts
- 5.4. Opthea Limited Industry Analysis
 - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
 - 5.4.2. Opthea Limited Industry Position Analysis

6. OPTHEA LIMITED NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

7. OPTHEA LIMITED EXPERTS REVIEW¹

- 7.1. Experts Consensus
- 7.2. Experts Revisions

8. OPTHEA LIMITED ENHANCED SWOT ANALYSIS²

9. AUSTRALIA PESTEL ANALYSIS²

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

10. OPTHEA LIMITED IFE, EFE, IE MATRICES²

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

11. OPTHEA LIMITED PORTER FIVE FORCES ANALYSIS²

12. OPTHEA LIMITED VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

Opthea Limited Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit

Profit Margin Chart

Operating Margin Chart

Return on Equity (ROE) Chart

Return on Assets (ROA) Chart

Debt to Equity Chart

Current Ratio Chart

Opthea Limited 1-year Stock Charts

Opthea Limited 5-year Stock Charts

Opthea Limited vs. Main Indexes 1-year Stock Chart

Opthea Limited vs. Direct Competitors 1-year Stock Charts

Opthea Limited Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

Opthea Limited Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Opthea Limited Key Executives
Opthea Limited Major Shareholders
Opthea Limited History
Opthea Limited Products
Revenues by Segment
Revenues by Region
Opthea Limited Offices and Representations
Opthea Limited SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Opthea Limited Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Opthea Limited Capital Market Snapshot
Opthea Limited Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics

Opthea Limited Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Opthea Limited Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3x3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

Sociological – What cultural and societal aspects will work upon the demand for the business's products and operations?

Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors

integrated into one suggestive model.

Porter Five Forces Analysis

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources

Financial

Physical

Technological

Organizational

Intangible resources

Human

Innovation and Creativity

Reputation

Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?

Rare?

Costly to imitate?

Organized properly?

I would like to order

Product name: Opthea Limited Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Product link: <https://marketpublishers.com/r/CFC55EDCC6EBEN.html>

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CFC55EDCC6EBEN.html>